Harald Herrmann

TL;DR: The results establish small-molecule inhibition of Brd4 as a promising therapeutic strategy in AML and, potentially, other cancers, and highlight the utility of RNA interference screening for revealing epigenetic vulnerabilities that can be exploited for direct pharmacological intervention.

TL;DR: More precise reporting of the parameters that are used to identify CSCs and to attribute responses to them is recommended as key to accelerating an understanding of their biology and developing more effective methods for their eradication in patients.

TL;DR: It is shown that the expression level of the transcription factor STAT5 is another parameter that determines the sensitivity of BCR-ABL1(+) cells against tyrosine kinase inhibitors (TKIs), and suggests that STAT5 may serve as an attractive target to overcome imatinib resistance in BCR(+) leukemia.

TL;DR: Dasatinib exerts growth‐inhibitory effects in patients with imatinib‐resistant chronic myeloid leukaemia and side effects were reported to be mild and tolerable in first clinical trials.

TL;DR: New developments in the field of CSC research are discussed and whether these new concepts can be exploited in clinical practice in the future.